Randomized trial · people
Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this Japanese trial, dulaglutide 0.75 mg lowered blood sugar but did little to body weight, and tirzepatide lowered both more, with more nausea.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 636
- Published
- 2022
- Journal
- Lancet Diabetes Endocrinol
What they tested
The team tested whether weekly tirzepatide at 5, 10 or 15 mg controlled blood sugar and body weight better than weekly dulaglutide 0.75 mg in Japanese people with type 2 diabetes.
How the study was done
A double-blind (neither patients nor doctors knew who got which drug), randomized, phase 3 trial at 46 centers in Japan in 636 adults with type 2 diabetes who were new to treatment or had stopped a single oral diabetes drug. Equal-sized groups got one of four weekly shots for 52 weeks: dulaglutide at 0.75 mg, or tirzepatide at a dose of 5 mg, 10 mg or 15 mg.

Model. Individual results vary.
What they found
At week 52, HbA1c (a 3-month average of blood sugar) fell by 1.3 in the dulaglutide arm, compared with 2.4, 2.6 and 2.8 in the tirzepatide 5, 10 and 15 mg arms. Against dulaglutide, the extra drop with tirzepatide ranged from 1.1 to 1.5 (all p<0.0001). Body weight changed by -0.5 kg (-0.7%) with dulaglutide, versus -5.8 kg, -8.5 kg and -10.7 kg (-7.8%, -11.0% and -13.9%) across the tirzepatide arms. Nausea affected 8% of the dulaglutide group and 12% to 20% of the tirzepatide groups; constipation affected 11% versus 14% to 18%.
What it doesn’t show
Dulaglutide was tested only at 0.75 mg, and the trial included only Japanese adults, about three quarters of them men, for 52 weeks. It was funded by Eli Lilly and Company.
The paper
Inagaki et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022.
The compounds
More studies on Dulaglutide
- Mazdutide beat dulaglutide on HbA1c and weight at 28 weeksRandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Dulaglutide lowered major cardiovascular events (HR 0.88) in REWINDRandomized trial · people · 2019
- Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7Randomized trial · people · 2018
- 5-Amino-1MQ slowed bladder tumor growth in miceAnimal study · mice · 2024
- MOTS-c prevented muscle atrophy, raised muscle glucose uptake in miceAnimal study · mice · 2024
- Every study on Dulaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.